Direclidine - Neurocrine Biosciences
Alternative Names: HTL-0016878; NBI-1117568; NBI-568Latest Information Update: 18 Nov 2025
At a glance
- Originator Heptares Therapeutics
- Developer AbbVie; Neurocrine Biosciences; Nxera Pharma
- Class Antidementias; Antipsychotics; Carbamates; Piperazines; Pyrazoles; Pyrrolidines; Small molecules; Spiro compounds
- Mechanism of Action Muscarinic M4 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Schizophrenia
- No development reported Alzheimer's disease
Most Recent Events
- 13 Nov 2025 Neurocrine Biosciences plans a phase III trial for Schizophrenia (Treatment-experienced) in December 2025 (Oral, Capsule) (NCT07227818)
- 16 Sep 2025 Chemical structure information added.
- 11 Aug 2025 Neurocrine Biosciences initiates a phase III trial for Schizophrenia (PO) in USA (NCT07105098)